Core Viewpoint - The company has approved a plan to manage temporarily idle raised funds through cash management, aiming to enhance fund utilization efficiency while ensuring the safety and intended use of the funds [1][3][7] Cash Management Overview - The purpose of cash management is to improve the efficiency of raised fund usage and generate additional returns for the company and its shareholders, without affecting the normal operation of investment projects [1][3] - The company plans to invest up to RMB 2.4 billion in safe, liquid principal-protected investment products, including but not limited to time deposits and structured deposits, within a 12-month period [1][3] - The funds for cash management will come from temporarily idle raised funds from the company's 2022 A-share issuance [1][3] Implementation and Oversight - The board of directors has authorized the chairman to make investment decisions and sign relevant legal documents, with the finance department responsible for implementation [2][3] - The company will adhere to regulatory requirements for information disclosure and will not change the intended use of the raised funds [2][3] Impact on Daily Operations - The cash management plan will not affect the normal cash flow needs or the operation of investment projects, ensuring that the company's main business continues to develop normally [6][7] - As of June 30, 2025, all initial public offering projects have been completed, and the raised funds will be used in accordance with the overall project schedule [6][7] Opinions from Intermediaries - The company's sponsor, Guotai Junan Securities, has confirmed that the cash management plan complies with relevant regulations and will not change the intended use of the raised funds, thus benefiting the company and its shareholders [7]

Core Viewpoint - Junshi Biosciences plans to utilize up to 2.4 billion yuan of temporarily idle raised funds for cash management to enhance fund efficiency and returns for the company and its shareholders [1] Group 1: Cash Management Purpose - The purpose of cash management is to improve the efficiency of raised funds and to reasonably utilize temporarily idle funds while ensuring that it does not affect the construction and use of investment projects [1] - The company aims to increase returns for both the company and its shareholders through this cash management strategy [1] Group 2: Investment Strategy - Junshi Biosciences will strictly control risks according to relevant regulations and intends to invest in high-safety, liquid principal-protected investment products [1] - The investment products include but are not limited to notice deposits, time deposits, agreement deposits, combination deposits, certificates of deposit, and structured deposits [1] - The funds will not be used for pledging or for investment purposes in securities [1]

Core Viewpoint - Junshi Biosciences (01877) plans to invest temporarily idle raised funds in low-risk, high-liquidity principal-protected investment products, adhering to relevant regulations [1] Group 1: Investment Strategy - The company intends to use a maximum of RMB 2.4 billion (including principal) of temporarily idle raised funds for cash management [1] - Investment products include but are not limited to notice deposits, time deposits, agreement deposits, combination deposits, certificates of deposit, and structured deposits [1] - The investment will not be used for pledging or for securities investment purposes [1] Group 2: Investment Duration and Management - The company plans to invest the idle funds in tranches with varying maturities, with the longest maturity not exceeding 12 months [1] - Within the specified limit and duration, the funds can be used in a rolling manner [1]